ID   HeLa SLC35A1 KO
AC   CVCL_E2QI
SY   HELA-SLC35A1-KO
DR   DSMZ; ACC-989
RX   PubMed=34069698;
CC   Population: African American.
CC   Doubling time: ~15-25 hours (DSMZ=ACC-989).
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; 11021; SLC35A1.
CC   Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
ST   Source(s): DSMZ=ACC-989
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 12,13.3
ST   D16S539: 9,10
ST   D18S51: 16
ST   D19S433: 13,14
ST   D21S11: 27
ST   D2S1338: 17
ST   D3S1358: 15,18
ST   D5S818: 11,12
ST   D7S820: 8,9,12
ST   D8S1179: 12
ST   FGA: 18,21
ST   Penta D: 8
ST   Penta E: 7,17
ST   TH01: 7
ST   TPOX: 12
ST   vWA: 16,18
DI   NCIt; C27677; Human papillomavirus-related cervical adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0030 ! HeLa
SX   Female
AG   30Y6M
CA   Cancer cell line
DT   Created: 10-09-24; Last updated: 10-09-24; Version: 1
//
RX   PubMed=34069698; DOI=10.3390/cells10051259; PMCID=PMC8160606;
RA   Banning A., Zakrzewicz A., Chen X., Gray S.J., Tikkanen R.;
RT   "Knockout of the CMP-sialic acid transporter SLC35A1 in human cell
RT   lines increases transduction efficiency of adeno-associated virus 9:
RT   implications for gene therapy potency assays.";
RL   Cells 10:1259.1-1259.14(2021).
//